Leading researcher describes the expanded endocannabinoidome as a platform for non-psychoactive cannabinoid therapies and gut-brain connections

The endocannabinoidome, an expanded network of endocannabinoid-like mediators and receptors, provides targets for non-psychoactive cannabinoids like CBD and connects to the gut microbiome's role in neuropsychiatric disorders.

Di Marzo, Vincenzo·Dialogues in clinical neuroscience·2020·Moderate EvidenceReview
RTHC-02517ReviewModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The endocannabinoidome extends beyond classical CB1/CB2 to include numerous lipid mediators, receptors, and enzymes involved in neuropsychiatric disorders. Non-euphoric plant cannabinoids like CBD have a wide therapeutic window because they hit multiple eCBome targets. The eCBome also connects to the microbiota-gut-brain axis, emerging as important for affective and cognitive functions.

Key Numbers

No specific effect sizes; the review provides a conceptual framework connecting the eCBome, plant cannabinoids, and the gut-brain axis.

How They Did This

Expert review by Vincenzo Di Marzo (a pioneer of endocannabinoid research) covering the eCBome concept, its role in neuropsychiatric disorders, the pharmacology of non-psychoactive cannabinoids, and the gut-brain connection.

Why This Research Matters

This framework from a leading researcher explains why CBD may help diverse neuropsychiatric conditions and introduces the gut microbiome as a new frontier for understanding cannabinoid therapeutics.

The Bigger Picture

The connection between the endocannabinoidome and gut microbiome opens entirely new avenues for understanding how cannabis and cannabinoids affect mental health, potentially through mechanisms unrelated to traditional brain receptor pharmacology.

What This Study Doesn't Tell Us

Conceptual review by a single author; many proposed connections are still theoretical; the gut-brain-eCBome axis in humans remains poorly characterized.

Questions This Raises

  • ?Can gut microbiome interventions enhance or mimic cannabinoid effects on mental health?
  • ?Which specific eCBome targets explain CBD's therapeutic effects?

Trust & Context

Key Stat:
CBD's wide therapeutic window may come from hitting multiple eCBome targets simultaneously
Evidence Grade:
Expert review from a field pioneer providing conceptual framework rather than new data.
Study Age:
Published in 2020.
Original Title:
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.
Published In:
Dialogues in clinical neuroscience, 22(3), 259-269 (2020)
Authors:
Di Marzo, Vincenzo(23)
Database ID:
RTHC-02517

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What is the endocannabinoidome?

It is an expanded version of the endocannabinoid system that includes not just CB1/CB2 and their ligands, but dozens of related lipid mediators, their receptors, and enzymes. This expanded network helps explain why cannabinoids affect so many different body systems.

How does the gut microbiome connect to cannabinoids?

The endocannabinoidome plays a role in the microbiota-gut-brain axis, a communication system between gut bacteria and the brain. Disruptions in this system are linked to mood and cognitive disorders, and cannabinoids may influence mental health partly through gut-level effects.

Read More on RethinkTHC

Cite This Study

RTHC-02517·https://rethinkthc.com/research/RTHC-02517

APA

Di Marzo, Vincenzo. (2020). The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.. Dialogues in clinical neuroscience, 22(3), 259-269. https://doi.org/10.31887/DCNS.2020.22.3/vdimarzo

MLA

Di Marzo, Vincenzo. "The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.." Dialogues in clinical neuroscience, 2020. https://doi.org/10.31887/DCNS.2020.22.3/vdimarzo

RethinkTHC

RethinkTHC Research Database. "The endocannabinoidome as a substrate for noneuphoric phytoc..." RTHC-02517. Retrieved from https://rethinkthc.com/research/di-2020-the-endocannabinoidome-as-a

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.